Biorem Reports Record Order Backlog, - $11.3 Million of Revenues in the Quarter and Quarterly EPS of $0.07

Executive Summary

• Biorem reported Q3 2025 revenue of $11.3 M (up 19% QoQ) and EPS of $0.07, with a record order backlog of $71 M as of September 30, 2025.
• Net earnings for the quarter were $1.6 M; cash on hand increased to $8.4 M and working capital rose to $11.7 M.
• The company booked $17 M of new orders during the quarter, projecting continued order‑booking growth and revenue expansion over the next 12 months.

Key Details

• Revenue: $11,253 k (Q3 2025) vs. $14,886 k (Q3 2024); YTD $25,414 k vs. $28,104 k (2024).
• Gross Profit: $3,166 k (Q3 2025) – 28% of revenue; down from $5,021 k (33%) in Q3 2024.
• Operating Expenses: $1,552 k (Q3 2025) vs. $1,992 k (Q3 2024).
• EBITDA: $1,707 k (Q3 2025) vs. $3,138 k (Q3 2024).
• Net Earnings: $1,158 k (Q3 2025) vs. $2,192 k (Q3 2024).
• EPS – Basic: $0.07 (Q3 2025) vs. $0.14 (Q3 2024).
• EPS – Fully Diluted: $0.06 (Q3 2025) vs. $0.12 (Q3 2024).
• Order Backlog: Record $71 M on Sep 30, 2025; up from $50.9 M on Jun 30, 2025 and $48.4 M on Sep 30, 2024.
• New Orders Booked: $17 M during Q3 2025.
• Cash Position: Cash on hand $8.4 M (Sep 30, 2025); working capital $11.7 M.
• Operating Cash Flow: Generated $1.7 M of cash; net increase in non‑cash working capital used $0.807 M of cash.

Notable Quotes

“A multi‑pronged effort by the sales team across the various product categories has resulted in strong order bookings and order backlog growth,” said Derek S. Webb, President & CEO.
“With a historic order backlog and continued bookings growth anticipated, Biorem is continuing on its growth trajectory.”